stock.name

Zoetis Inc - Ordinary Shares - Class A

ZTS

Market Cap$77.07B
Close$

Compare Zoetis- Ordinary Shares

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Zoetis Inc - Ordinary Shares - Class AZoetis Inc - Ordinary Shares - Class A32.90.92%47%9.41.3
marketMarket Avg59.61.27%31%6.41
HealthcareHealthcare Avg62.31.27%15%7.30.9

Earnings Call Q4 2023

February 14, 2024 - AI Summary

Zoetis reported strong full-year 2023 results, with revenue of $8.5 billion and adjusted net income of $2.5 billion.
The company achieved 7% operational revenue growth, driven by steady demand for innovative products in both the companion animal and livestock portfolios.
Key growth drivers included the success of monoclonal antibodies for osteoarthritis pain (Librela and Solensia), the dermatology franchise, and the Simparica Trio parasiticides portfolio.

Exclusive for Stockcircle Pro members

Sign upSign Up
$176.18

Current Fair Value

4.5% upside

Undervalued by 4.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$77.07 Billion
Enterprise Value$81.59 Billion
Dividend Yield$1.5518 (0.92%)
Earnings per Share$5.07
Beta1.02
Outstanding Shares457,867,115
Avg 30 Day Volume3,737,111

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio32.88
PEG236.83
Price to Sales9.36
Price to Book Ratio16.85
Enterprise Value to Revenue9.55
Enterprise Value to EBIT26.56
Enterprise Value to Net Income34
Total Debt to Enterprise0.08
Debt to Equity1.31

Revenue Sources

No data

ESG Score

No data

About Zoetis Inc

9,200 employees
CEO: Kristin Peck

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines...